I don't know Seuss, it was a pretty damn impressive CC (and I've listened to a lot of them).
Right now the company is, indeed, better off than it was in Feb. and trading around $29. They will know in about 2 weeks if they on for Dec with the FDA. The data looks very good - the extra 6 month unblinded data is virtually undeniable. As they said in the CC, being a "preventative" is what has the most clinical relevance, and 50% reduction is a huge percentage in this field. I believe they said only 1 patient failed to have a positive reaction. We should also get some prostrate data soon as well (huge market there). Nothing in this world is certain, but FDA approval here has gone from "possible" to "likely".
They are gearing up inventory for commercial rollout, and looking for
a marketing alliance. (Reminds me of IMCL's move to build the production facility for their P3 drug.)
The death knell for the shorts will be additional analyst coverage. The drug is ophan statused, fast tracked, and the last paperwork for the NDA will be filled Monday. It's almost inconcievable that we won't see some serious institutional attention very soon. At that point all these shorts will be nothing more than fuel for the fire.
If you honestly think anything said sounded so bad, then short away on excellent news - with prospects for even more excellent news. Seuss, I short stocks all the time - it's all part of the game. But the short game is over on this one, and everyone knows it.
The more shorts the better at this point. Love all the latent buying already build into this stock. I think we could see a combined FDA approval run and short squeeze that will be nothing less than spectactular.
We'll probably just continue to consolidate (I hope to double my position) until the Dec FDA meeting is confirmed by second week of Nov...then it's off to the races...IMHO...
Oh...and btw...the talk about possible "illegal shorts" in the stock was a legitimate concern. I think all longs should lock down their shares with a GTC sell order (at some high remote price), or use their cash accounts. If you consider that only about 10 mil shares are in the general float, and over 3.5 mil are short, its one little way longs can help the price (outside of just buying more). I'll admit, it's a nasty thing to do to the shorts <GGGGG>
SM |
